CLINICAL RESEARCH: ATHEROSCLEROSIS
Polymorphisms of KDR Gene Are Associated With Coronary Heart Disease
Yibo Wang, PhD*,
Yi Zheng, MD*,
Weili Zhang, PhD*,
Hui Yu, MS*,
Kejia Lou*,
Yu Zhang*,
Qin Qin, MD ,
Bingrang Zhao, MD,
Ying Yang, MD and
Rutai Hui, MD, PhD*,*
* Key Laboratory for Clinical Cardiovascular Genetics, Ministry of Education, China and Sino-German Laboratory for Molecular Medicine, and the Department of Cardiology, Cardiovascular Institute and FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Tianjin Cardiovascular Institute and Tianjin Chest Hospital, Tianjin, China
Qingdao FuWai Hospital, Shandong, China.
Manuscript received December 5, 2006;
revised manuscript received April 19, 2007,
accepted April 24, 2007.
* Reprint requests and correspondence: Dr. Rutai Hui, Cardiovascular Institute and FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishilu, Beijing 100037, People’s Republic of China. (Email: huirutai{at}sglab.org).
Objectives: Our purpose was to determine whether the common polymorphisms (SNP-604, SNP1192, and SNP1719) in KDR are associated with risk of coronary heart disease.
Background: Vascular endothelial growth factor (VEGF) and its receptor KDR (kinase insert domain-containing receptor/fetal liver kinase-1, also called VEGFR2) play critical roles in angiogenesis and vascular repair, which are involved in the progress of coronary heart disease.
Methods: The association of the 3 polymorphisms with risk of coronary heart disease was determined in 2 independent case-control studies: one comprised of 665 patients with coronary heart disease and 1,015 control subjects, and the other comprised of 369 patients and 625 control subjects. The SNP functions of KDR gene were studied by using luciferase reporter assays, determination of serum levels of KDR, and ligand-binding assays.
Results: The 2 independent population studies showed that the 3 polymorphisms were associated with risk of coronary heart disease with odds ratios of 1.37 for SNP-604 (p = 0.006), 1.41 for SNP1192 (p = 0.011), and 1.37 for SNP1719 (p = 0.007) in the first population, and 1.40 for SNP-604 (p = 0.015), 1.75 for SNP1192 (p = 0.003), and 1.50 for SNP1719 (p = 0.010) in the second population. The SNP-604C–bearing KDR promoter exhibited 68% of lower transcription activity than the SNP-604T–bearing promoter. The SNP1192 and SNP1719 could obviously influence the efficiency of VEGF binding to KDR.
Conclusions: The KDR polymorphisms may serve as novel genetic markers for the risk of coronary heart disease.
|
Abbreviations and Acronyms
| | BMI = body mass index | | CHD = coronary heart disease | | DM = diabetes mellitus | | EPC = endothelial progenitor cell | | HDL-C = high-density lipoprotein cholesterol | | KDR
= kinase insert domain-containing receptor | | PCR = polymerase chain reaction | | TC = total plasma cholesterol | | TG = triglycerides | | SNP = single nucleotide polymorphism | | VEGF = vascular endothelial growth factor |
|
This article has been cited by other articles:
|
|
|
|
 
D. M. Glubb, E. Cerri, A. Giese, W. Zhang, O. Mirza, E. E. Thompson, P. Chen, S. Das, J. Jassem, W. Rzyman, et al.
Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer
Clin. Cancer Res.,
August 15, 2011;
17(16):
5257 - 5267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-F. Xu, N. X. Bing, H. A. Ball, D. Rajagopalan, C. N. Sternberg, T. E. Hutson, P. de Souza, Z. G. Xue, L. McCann, K. S. King, et al.
Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
J. Clin. Oncol.,
June 20, 2011;
29(18):
2557 - 2564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pander, J. A. M. Wessels, H. Gelderblom, T. van der Straaten, C. J. A. Punt, and H.- J. Guchelaar
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer
Ann. Onc.,
May 1, 2011;
22(5):
1147 - 1153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-T. Su, S.-H. Lin, I.-W. Lee, Y.-C. Chen, and P.-L. Kuo
Association of polymorphisms/haplotypes of the genes encoding vascular endothelial growth factor and its KDR receptor with recurrent pregnancy loss
Hum. Reprod.,
April 1, 2011;
26(4):
758 - 764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Pabst, A. Karpushova, A. Diaz-Lacava, S. Herms, M. Walier, S. Zimmer, S. Cichon, G. Nickenig, M. M. Nothen, T. F. Wienker, et al.
VEGF Gene Haplotypes Are Associated With Sarcoidosis
Chest,
January 1, 2010;
137(1):
156 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. van Erp, K. Eechoute, A. A. van der Veldt, J. B. Haanen, A. K.L. Reyners, R. H.J. Mathijssen, E. Boven, T. van der Straaten, R. F. Baak-Pablo, J. A.M. Wessels, et al.
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
J. Clin. Oncol.,
September 10, 2009;
27(26):
4406 - 4412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Zhang, K. Sun, Y. Zhen, D. Wang, Y. Wang, J. Chen, J. Xu, F. B. Hu, and R. Hui
VEGF Receptor-2 Variants Are Associated With Susceptibility to Stroke and Recurrence
Stroke,
August 1, 2009;
40(8):
2720 - 2726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
